



Product Specification Sheet

Product Name: LY-2228820

Catalog Number: C5922

Technical information:

Chemical Formula: $C_{24}H_{29}FN_{6.2}CH_4O_3S$

CAS #: 862507-23-1

Molecular Weight: 612.74

Purity: > 98%


Appearance: Off-white solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: 5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate

Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



LY-2228820

- Handling:**
- To make 10 mM stock solution, add 0.163mL of DMSO for each mg of LY-2228820.
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: LY2228820 is a potent and selective ATP-competitive inhibitor of the α - and β -isoforms of p38 mitogen-activated protein kinases (MAPKs). It inhibits p38 α and p38 β with IC50 values of 5.3 nM and 3.2 nM, respectively. [1] In cell-based assays, LY2228820 selectively inhibited the level of phospho-MAPKAP-K2 (pMK2) in anisomycin-induced RAW264.7 cells, with IC50 of 35.3 nM. LY2228820 also inhibits lipopolysaccharide (LPS)/IFN- γ -induced TNF α formation in murine peritoneal macrophages, with IC50 of 6.3 nM. [1] Furthermore, LY2228820 inhibits angiogenic endothelial cord formation in multiple in vitro and in vivo assay models. [2] LY2228820 is currently being evaluated in Phase I/II clinical trials in patients with newly diagnosed glioblastoma [3] and platinum-sensitive ovarian cancer [4]."

- Reference:**
1. Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014; 13(2):364-74 Pubmed ID: 24356814
 2. Tate CM, et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem. 2013; 288(9):6743-53 Pubmed ID: 23335506
 3. <https://clinicaltrials.gov/ct2/show/NCT02364206> Pubmed ID: NCT02364206
 4. <https://clinicaltrials.gov/ct2/show/NCT01663857> Pubmed ID: NCT01663857

To reorder: <http://www.cellagentech.com/LY-2228820/>

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.